VO-OHPic is a reversible, noncompetitive, and selective inhibitor of PTEN with an IC50 of 46 nM. It effectively attenuates apoptosis, adverse cardiac remodeling, and the presence of pro-inflammatory M1 macrophages in models of doxorubicin-induced cardiomyopathy. Additionally, VO-OHPic inhibits autophagy [1] [2] [3].
T0467 is a chemical compound that activates the translocation of parkin to the mitochondria in a PINK1-dependent manner in vitro. However, T0467 does not induce the accumulation of PINK1 in the mitochondria of dopaminergic neurons. As a result, T0467 shows promise as a potential compound for activating the PINK1-Parkin signaling pathway and can be utilized in research related to Parkinson's disease and related disorders.
FT3967385 is a newly developed compound that functions as a USP30 inhibitor, emulating the genetic deficiency of USP30. This inhibition serves as a catalyst for the amplification of mitochondrial ubiquitylation through the PINK1-PARKIN pathway.